Header

Solid Tumor/Phase I Clinical Trials

Category:Adult
Status:Active

Displaying trials 1 - 30 of 93 in total

An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification

This is an open-label, multicenter, multinational, Phase 2 study exploring the efficacy and safety of neratinib therapy in patients with solid tumors with activating HER2, HER3 or EGFR mutations or...

Diagnosis: Solid Tumor/Phase I

Phase: 2

Protocol Number: 13-615

Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)

Phase II, multi-center, open-label study of patients with advanced solid tumors harboring a fusion of NTRK1, NTRK2 or NTRK3.

Diagnosis: Solid Tumor/Phase I

Phase: 2

Protocol Number:

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

This phase Ib/II trial studies the side effects and best dose of trametinib and navitoclax in treating patients with solid tumors that have spread to other places in the body or cannot be cured or ...

Diagnosis: Solid Tumor/Phase I

Phase: 1 / 2

Protocol Number: 13-505

Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma

The purpose of this study is to determine which doses of Urelumab and Nivolumab are safe and tolerable when they are given together.

Diagnosis: Solid Tumor/Phase I, Non-Hodgkin's Lymphoma

Phase: 1 / 2

Protocol Number: 15-207

A Study to Investigate the Safety and Efficacy of Nivolumab and Nivolumab Plus Ipilimumab in Virus-associated Tumors

The purpose of this study to investigate the safety and efficacy of using nivolumab, and nivolumab in combination with ipilimumab, to treat subjects who have virus-associated tumors. Certain viruse...

Diagnosis: Solid Tumor/Phase I

Phase: 1 / 2

Protocol Number: 15-423

A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioblastoma

The main purpose of this study is to evaluate the safety, tolerability, and efficacy of the study drug known as galunisertib in combination with nivolumab in participants with advanced refractory s...

Diagnosis: Solid Tumor/Phase I, Lung Cancer, Brain/Neuro Cancer: Newly Diagnosed

Phase: 1 / 2

Protocol Number: 15-557

A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers

This is an open label, multi-center, Phase 1/2 study of BBI608 administered in combination with immunotherapy in adult patients with advanced cancers. The goal of the study is to determine the RP2D...

Diagnosis: Solid Tumor/Phase I

Phase: 1 / 2

Protocol Number: 15-346

Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

The purpose of this first-in-human study of MBG453 is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of MBG453 administered i.v. as a single ag...

Diagnosis: Solid Tumor/Phase I

Phase: 1 / 2

Protocol Number: 16-214

Study CB-839 in Combination With Nivolumab in Patients With ccRCC and Other Solid Tumors

This study is an open-label Phase 1/ 2 evaluation of CB-839 in combination with nivolumab in patients with clear cell renal cell carcinoma, melanoma, and non-small cell lung cancer.

Diagnosis: Solid Tumor/Phase I

Phase: 1 / 2

Protocol Number: 16-379

A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

PF-02341066 may work in cancer by blocking the cell growth, migration and invasion of tumor cells. PF-02341066 is a new class of drugs called c-Met/Hepatocyte growth factor receptor tyrosine kinase...

Diagnosis: Solid Tumor/Phase I

Phase: 1

Protocol Number:

Irinotecan Hydrochloride and Veliparib in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery

This phase I trial is studying the side effects and best dose of irinotecan given together with ABT-888 in treating patients with metastatic or unresectable cancer. Drugs used in chemotherapy, such...

Diagnosis: Solid Tumor/Phase I

Phase: 1

Protocol Number: 08-121

A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors

The primary objective of this study is to determine the maximum tolerated dose (MTD) or recommended phase II doses of sapacitabine and seliciclib administered sequentially or concomitantly. The sec...

Diagnosis: Solid Tumor/Phase I

Phase: 1

Protocol Number: 08-271

Safety Study of MGA271 in Refractory Cancer

The purpose of this study is to evaluate the safety of MGA271 when given by intravenous (IV) infusion to patients with refractory cancer. The study will also evaluate how long MGA271 stays in the b...

Diagnosis: Solid Tumor/Phase I

Phase: 1

Protocol Number: 11-217

Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors

This phase I trial studies the side effects and the best dose of veliparib and dinaciclib in treating patients with solid tumors that have spread to other places in the body and usually cannot be c...

Diagnosis: Solid Tumor/Phase I

Phase: 1

Protocol Number: 11-144

A Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors

To assess the safety and tolerability and preliminary anti-tumor activity of lirilumab/BMS-986015 given in combination with nivolumab/BMS-936558 and to identify dose limiting toxicities (DLTs) and ...

Diagnosis: Solid Tumor/Phase I

Phase: 1

Protocol Number: 12-487

Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations

This study is primarily designed to assess the safety and the tolerability of Debio1347 (CH5183284) in patients with advanced solid malignancies, whose tumours have an alteration of the Fibroblast ...

Diagnosis: Solid Tumor/Phase I

Phase: 1

Protocol Number: 13-251

A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents

This study will evaluate PF-05212384 (PI3K/mTOR inhibitor) in combination with either docetaxel, cisplatin or dacomitinib in select advanced solid tumors. The study will assess the safety, pharmaco...

Diagnosis: Solid Tumor/Phase I

Phase: 1

Protocol Number: 13-382

Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

To assess the safety and tolerability, characterize the dose-limiting toxicities, and identify the maximum tolerated dose of BMS-986016 alone and in combination with Nivolumab in subjects with sele...

Diagnosis: Solid Tumor/Phase I

Phase: 1

Protocol Number:

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

This phase I trial studies the side effects and best dose of raptor/rictor-mammalian target of rapamycin (mTOR) (TORC1/2) inhibitor MLN0128 when given in combination with bevacizumab in treating pa...

Diagnosis: Solid Tumor/Phase I

Phase: 1

Protocol Number: 14-079

A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors

Despite the success of anti-angiogenic therapy in multiple treatment settings, a fraction of patients are refractory to vascular endothelial growth factor (VEGF) inhibitor treatment, while the majo...

Diagnosis: Solid Tumor/Phase I

Phase: 1

Protocol Number:

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Many tumor cells, in contrast to normal cells, have been shown to require the amino acid glutamine to produce energy for growth and survival. To exploit the dependence of tumors on glutamine, CB-83...

Diagnosis: Solid Tumor/Phase I

Phase: 1

Protocol Number: 14-455

Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors

This phase I trial studies the side effects and best dose of ziv-aflibercept when given together with pembrolizumab in treating patients with solid tumors that have spread to other places in the bo...

Diagnosis: Solid Tumor/Phase I

Phase: 1

Protocol Number: 15-703

A Phase 1B Study of MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Patients With Advanced Nonhematologic Malignancies

The primary purpose of this study is to determine the safety profile and the maximum tolerated doses (MTDs/potential recommended phase 2 doses (RP2Ds) of the combination treatments of MLN2480 + MLN...

Diagnosis: Solid Tumor/Phase I

Phase: 1

Protocol Number: 14-537

Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer

The purpose of this study is to assess safety of nab-paclitaxel based chemotherapy regimens administered prior to and/or in combination with nivolumab in Pancreatic Cancer, Non Small Cell Lung Canc...

Diagnosis: Solid Tumor/Phase I

Phase: 1

Protocol Number: 15-074

A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers

This is an open-label, single arm, dose escalation study in patients with advanced cancers.

Diagnosis: Solid Tumor/Phase I

Phase: 1

Protocol Number: 15-281

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

This study evaluates the anti-tumor effects of ALRN-6924 in patients with advanced solid tumors or lymphomas with WT TP53.

Diagnosis: Lymphoma, Solid Tumor/Phase I

Phase: 1

Protocol Number:

A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

This is a Phase 1b, open label, multi-center study of CMB305 (sequentially administered LV305 [a dendritic cell-targeting viral vector expressing the NY-ESO-1 gene] and G305 [NY-ESO-1 recombinant p...

Diagnosis: Solid Tumor/Phase I

Phase: 1

Protocol Number:

A Study to Evaluate the Safety and Pharmacokinetics of KTN0158 in Adult Patients With Advanced Solid Tumors

This is a dose-escalation Phase 1 study designed to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose, and the safety profile of KTN0158 in patients with KIT-positive advan...

Diagnosis: Solid Tumor/Phase I

Phase: 1

Protocol Number: 15-577

Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors

This is a three-part, open-label, safety, tolerability, and PK study of FPA144. Patients will be enrolled in Part 1 (A or B, dose escalation) or Part 2 (dose expansion) of the study, but not both.

Diagnosis: Solid Tumor/Phase I

Phase: 1

Protocol Number: 16-026

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants ...

Diagnosis: Solid Tumor/Phase I

Phase: 1

Protocol Number: 16-456

1
<< Previous
'